← ARROWHEAD PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $158k |
$31.4m
+19736.49%
|
$16.1m
-48.60%
|
$168.8m
+945.67%
|
$88.0m
-47.87%
|
$138.3m
+57.16%
|
$243.2m
+75.89%
|
$240.7m
-1.03%
|
$3.6m
-98.52%
|
$829.4m
+23258.15%
|
$669.5m
-19.28%
|
|
| Research and Development Expense | — | — | — | — | — | — | — | — | — | $607.2m | $723.4m | |
| General and Administrative Expense | $9.9m | $6.8m | $19.1m | $26.6m | $52.3m | $81.0m | $124.4m | $92.5m | $98.8m | $123.9m | $170.6m | |
| Labor and Related Expense | $19.5m | $17.3m | — | — | — | — | — | — | — | — | — | |
| Amortization of Intangible Assets | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | $1.7m | — | |
| Operating Expenses | $81.9m | $68.4m | $72.1m | $107.6m | $181.2m | $287.3m | $421.7m | $445.7m | $604.6m | $731.1m | $895.9m | |
| Operating Income (Loss) | ($81.7m) |
($37.0m)
+54.74%
|
($55.9m)
-51.20%
|
$61.2m
+209.39%
|
($93.2m)
-252.24%
|
($149.0m)
-59.98%
|
($178.5m)
-19.77%
|
($205.0m)
-14.84%
|
($601.1m)
-193.21%
|
$98.3m
+116.36%
|
($226.4m)
-330.25%
|
|
| Gain (Loss) on Investments | — | — | — | — | — | — | ($4.4m) | $0 | — | — | — | |
| Other Nonoperating Income (Expense) | $57k | $1.3m | $7k | — | ($583k) | $2.1m | $765k | $1.5m | ($1.7m) | $5.3m | — | |
| Interest Expense (non-operating) | — | — | — | — | — | $0 | $0 | $18.3m | $32.4m | $89.4m | $92.6m | |
| Interest Income (Expense), Nonoperating, Net | $266k | $415k | $1.0m | $7.0m | $9.2m | $6.1m | $5.0m | — | — | — | $52.5m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | — | — | ($194.6m) | ($582.3m) | ($42.6m) | ($252.1m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($81.7m) | ($34.4m) | ($54.4m) | $68.1m | ($84.6m) | ($140.8m) | ($172.7m) | ($206.5m) | ($612.5m) | $51.5m | ($252.1m) | |
| Income Tax Expense (Benefit) | $2k | $2k | $2k | $174k | $2k | $2k | $3.8m | $2.8m | ($2.8m) | $21.4m | $20.0m | |
| Net Income (Loss) Attributable to Parent | ($81.7m) | — | — | $68.0m |
($84.6m)
-224.39%
|
($140.8m)
-66.58%
|
($176.1m)
-25.00%
|
($205.3m)
-16.59%
|
($599.5m)
-192.04%
|
($1.6m)
+99.73%
|
($320.0m)
-19517.11%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | — | $0 | $0 | ($431k) | ($4.0m) | ($10.2m) | $31.7m | ($320.0m) | |
| Earnings Per Share, Basic | — | ($0.47) | ($0.65) | $0.72 | ($0.84) | ($1.36) | ($1.67) | ($1.92) | ($5.00) | ($0.01) | ($2.28) | |
| Earnings Per Share, Diluted | ($1.34) | ($0.47) | ($0.65) | $0.69 | ($0.84) | ($1.36) | ($1.67) | ($1.92) | ($5.00) | ($0.01) | ($2.28) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 93.9m | 100.7m | 103.7m | 105.4m | 106.8m | 119.8m | 133.8m | 140.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 98.6m | 100.7m | 103.7m | 105.4m | 106.8m | 119.8m | 133.8m | 140.5m | |
| Additional Financial Items | ||||||||||||
| Income (Loss) Attributable to Parent, before Tax | — | — | — | — | $0 | $0 | $431k | ($202.5m) | ($612.5m) | $51.5m | — | |
| Realized Investment Gains (Losses) | — | — | — | — | — | — | — | — | ($80k) | $0 | — |